Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Omkar Pharmachem's 5-Year ROIIC % for the quarter that ended in Mar. 2026 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Omkar Pharmachem's 5-Year ROIIC % or its related term are showing as below:
BOM:532167's 5-Year ROIIC % is not ranked *
in the Business Services industry.
Industry Median: 5.53 * Ranked among companies with meaningful 5-Year ROIIC % only.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Omkar Pharmachem 5-Year ROIIC % Related Terms
Omkar Pharmachem 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Omkar Pharmachem's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:532167 vs CTAS, CPRT, GPN: 5-Year ROIIC % Comparison
For the Specialty Business Services subindustry, Omkar Pharmachem's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omkar Pharmachem 5-Year ROIIC % vs Business Services Industry
For the Business Services industry and Industrials sector, Omkar Pharmachem's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Omkar Pharmachem's 5-Year ROIIC % falls into.
Omkar Pharmachem's 5-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( 1.178415 (Mar. 2026) - 0 (Mar. 2021) )
/
( 364.66 (Mar. 2026) - 104.663 (Mar. 2021) )
=
/
259.997
=
0.00%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Omkar Pharmachem (BOM:532167) has a 5-Year ROIIC % of 0.00 as of Mar. 2026. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Omkar Pharmachem and its competitors. According to the industry distribution chart, Omkar Pharmachem ranks #999999 out of 890 companies in the Business Services industry.
Is Omkar Pharmachem's 5-Year ROIIC % too high?
Omkar Pharmachem's current 5-Year ROIIC % is 0.00. Based on the distribution chart, Omkar Pharmachem ranks #999999 out of 890 companies in the Business Services industry, which is in the bottom quartile relative to peers. Overall, Omkar Pharmachem has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Omkar Pharmachem's 5-Year ROIIC % compare to CTAS and CPRT?
According to the Business Services industry distribution chart, Omkar Pharmachem ranks #999999 out of 890 companies for 5-Year ROIIC %. This places Omkar Pharmachem in the lower half of its industry. The industry median 5-Year ROIIC % is 5.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Business Services company?
The median 5-Year ROIIC % among Business Services companies is 5.53, based on 890 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Omkar Pharmachem and its competitors. For the Business Services industry, the median 5-Year ROIIC % is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omkar Pharmachem's current 5-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omkar Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Omkar Pharmachem (BOM:532167) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹23.90, compared to a current price of ₹11.02 — trading 53.9% below its estimated fair value. The current 5-Year ROIIC % is 0.00. Omkar Pharmachem's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Omkar Pharmachem (BOM:532167), the current 5-Year ROIIC % is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Omkar Pharmachem (BOM:532167) Overvalued in 2026?
Based on GuruFocus' analysis, Omkar Pharmachem stock appears to be undervalued.
The current stock price of ₹11.02 is trading 53.9% below its estimated GF Value™ of ₹23.90.
GuruFocus considers Omkar Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:532167:
5-Year ROIIC %: 0.00
GF Value™: ₹23.90 vs. price of ₹11.02 (53.9% below fair value)
No single metric tells the full story. See the BOM:532167 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532167 has been successfully added to your 
